We appreciate the thoughtful Letter to the Editor by Drs. Finsterer and Zarrouk-Mahjoub [1] in response to our recent publication in Molecular Genetics and Metabolism: "8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease [2]". While the underlying pathophysiology of acute stroke-like episodes (SLEs) in mitochondrial disease remains incompletely understood, vascular endothelial dysfunction due to altered nitric oxide metabolism is the cause for at least a subset [3] [4] [5] [6] [7] [8] [9] . However, mitochondrial disease SLEs are due to dysfunction of CNS microvasculature, not large arteries, explaining their absence of a vascular distribution [10] . Similarly, we agree that rather than large vessel vasospasm, a pathophysiologic mismatch occurs between metabolic activity and microvascular flow. This is mediated by abnormal nitric oxide metabolism and results in insufficient blood flow to support neuronal metabolic demand [11] .
